Open Access

miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments

  • Authors:
    • Antonio Daniel Martinez‑Gutierrez
    • Oliver Millan Catalan
    • Rafael Vázquez‑Romo
    • Fany Iris Porras Reyes
    • Alberto Alvarado‑Miranda
    • Fernando Lara Medina
    • Juan E. Bargallo‑Rocha
    • Luz Tonatzin Orozco Moreno
    • David Cantú De León
    • Luis Alonso Herrera
    • César López‑Camarillo
    • Carlos Pérez‑Plasencia
    • Alma D. Campos‑Parra
  • View Affiliations

  • Published online on: July 30, 2019     https://doi.org/10.3892/ijmm.2019.4292
  • Pages: 1267-1280
  • Copyright: © Martinez‑Gutierrez et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Metastatic breast cancer (MBC) is a challenge for oncologists, and public efforts should focus on identifying additional molecular markers and therapeutic management to improve clinical outcomes. Among all diagnosed cases of breast cancer (BC; approximately 10%) involve metastatic disease; notably, approximately 40% of patients with early‑stage BC develop metastasis within 5 years. The management of MBC consists of systemic therapy. Despite different treatment options, the 5‑year survival rate is <20%, which may be due to a lack of response with de novo or acquired resistance. MicroRNAs (miRNAs or miRs) are promising biomarkers as they are readily detectable and have a broad spectrum and potential clinical applications. The aim of this study was to identify a miRNA profile for distinguishing patients with MBC who respond to systemic treatment. Patients with MBC were treated according to the National Comprehensive Cancer Network guidelines. We performed miRNA‑Seq on 9 primary tumors using the Thermo Fisher Scientific Ion S5 system. To obtain global miRNA profiles, we carried out differentially expressed gene elimination strategy (DEGES) analysis between the responsive and non‑responsive patients. The results identified a profile of 12 miRNAs associated with the response to systemic treatment. The data were validated in an independent cohort (TCGA database). Based on the results, the upregulation of miR‑342‑3p and miR‑187‑3p was associated with the response to systemic treatment, and with an increased progression‑free survival (PFS) and overall survival (OS); by contrast, the downregulation of miR‑301a‑3p was associated with a higher PFS and OS. On the whole, the findings of this study indicate that these miRNAs may serve as biomarkers for the response to systemic treatment or the prognosis of patients with MBC. However, these data should be validated experimentally in other robust cohorts and using different specimens before implementing these miRNAs as biomarkers in clinical practice to benefit this group of patients.

Related Articles

Journal Cover

October 2019
Volume 44 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Martinez‑Gutierrez, A.D., Catalan, O.M., Vázquez‑Romo, R., Porras Reyes, F.I., Alvarado‑Miranda, A., Lara Medina, F. ... Campos‑Parra, A. . (2019). miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments. International Journal of Molecular Medicine, 44, 1267-1280. https://doi.org/10.3892/ijmm.2019.4292
MLA
Martinez‑Gutierrez, A. D., Catalan, O. M., Vázquez‑Romo, R., Porras Reyes, F. I., Alvarado‑Miranda, A., Lara Medina, F., Bargallo‑Rocha, J. E., Orozco Moreno, L. T., Cantú De León, D., Herrera, L. A., López‑Camarillo, C., Pérez‑Plasencia, C., Campos‑Parra, A. ."miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments". International Journal of Molecular Medicine 44.4 (2019): 1267-1280.
Chicago
Martinez‑Gutierrez, A. D., Catalan, O. M., Vázquez‑Romo, R., Porras Reyes, F. I., Alvarado‑Miranda, A., Lara Medina, F., Bargallo‑Rocha, J. E., Orozco Moreno, L. T., Cantú De León, D., Herrera, L. A., López‑Camarillo, C., Pérez‑Plasencia, C., Campos‑Parra, A. ."miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments". International Journal of Molecular Medicine 44, no. 4 (2019): 1267-1280. https://doi.org/10.3892/ijmm.2019.4292